Acitretin and Cyclosporin A (Combination)

The combination of acitretin and cyclosporin A is used in the treatment of psoriasis, particularly in cases that are refractory to other treatments. This combination allows for lower doses of each medication to achieve superior therapeutic results with fewer side effects[1][5]. ## Mechanism and Usage Acitretin is a retinoid that normalizes cell differentiation and reduces inflammation, while cyclosporin A is an immunosuppressant that inhibits T-cell activation. When used together, they can provide complementary effects in treating psoriasis[1][2]. The combination may be used in several ways: - As part of sequential therapy, where cyclosporin A is used first for rapid improvement, followed by acitretin for maintenance therapy[3][4] - During transition phases between therapies to prevent rebound of psoriasis[9] - In combination therapy to increase efficacy while reducing the toxicity of each individual drug[5] ## Pharmacokinetic Interactions Research suggests that acitretin may enhance the oral bioavailability of cyclosporin A through inhibition of P-glycoprotein transporters in the intestine[6]. This interaction may lead to increased cyclosporin A concentrations in a time-dependent and dose-dependent manner, which could require close monitoring for optimal therapeutic outcomes[6]. ## Safety Considerations When using this combination: - Careful monitoring of triglycerides is warranted, as both agents can cause hypertriglyceridemia[5] - The combination has not consistently demonstrated additional benefits compared to monotherapy with either agent[8] - Some studies have reported failure of this combination in patients with erythrodermic psoriasis[8] ## Clinical Applications This combination may be particularly useful in: - Patients with multiple squamous cell carcinomas, as low doses of acitretin have shown efficacy in preventing recurrences of skin cancer[5] - As part of rotation, combination, or sequential therapy strategies for long-term psoriasis management[10] - Transitioning between therapies to reduce the risk of rebound, though the concurrent use period should be minimized and the cyclosporin dose decreased as quickly as possible[9] According to current guidelines, acitretin is the only systemic antipsoriatic agent that can be used in combination with another systemic drug without creating a regimen of two immunosuppressants[10], making it valuable in combination therapy approaches.